

The opinion in support of the decision being entered today was not written for publication and is not binding precedent of the Board.


UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Ex parte NEIL H. BANDER

Appeal No. 2006-0352¹
Application No. 09/929,546

ON BRIEF²



Before SCHEINER, MILLS and GRIMES, Administrative Patent Judges.

SCHEINER, Administrative Patent Judge.

DECISION ON APPEAL

This appeal involves a method of treating non-prostate cancer by administering monoclonal antibodies that bind prostate specific membrane antigen (PSMA). The examiner has rejected claims requiring a particular subgenus of anti-PSMA antibodies as lacking adequate written descriptive support. We have jurisdiction under 35 U.S.C. § 134. We will reverse this rejection because we find that appellant's disclosure conveys with reasonable clarity to those skilled in the art that, as of the filing date, appellant was in possession of the claimed invention.

¹ This appeal is related to appeals in related application nos. 09/357,709 (appeal no. 2006-0633), 09/357,710 (appeal no. 2006-1520) and 09/929,665 (appeal no. 2006-0632). We have considered these appeals together.

² Appellant requested an oral hearing in this case, however, after reviewing the case, we have determined that an oral hearing will not be necessary and have rendered a decision based on the record. See 37 CFR §§ 41.47(a),(f).

BACKGROUND

“PSMA is an integral membrane protein known to have a short intracellular tail and a long extracellular domain.” Specification, page 8. Various researchers have reported that “PSMA is prostate-specific and shows increased expression levels in metastatic sites and in hormone-refractory states” (id.); that “PSMA is more strongly expressed in prostate cancer cells relative to cells from the normal prostate or from a prostate with benign hyperplasia” (id.); and that “PSMA is not found in serum” (id.). On the other hand, according to appellant, “the vascular endothelial cells supplying blood to cancerous tissues . . . express an extracellular domain of [PSMA], irrespective of the type of cancer involved . . . [while] vascular endothelial cells supplying blood to normal tissues do not express an extracellular domain of [PSMA]” (id., page 17).

In any case, according to appellant, PSMA is “an attractive target for antibody mediated . . . imaging and therapy of [] cancer” (id., page 8). However, “antibody molecules do not, under normal circumstances, cross the cell membrane unless they bind to the extracellular portion of a molecule and become translocated intracellularly,” thus antibodies that bind the intracellular portion of PSMA “do[] not have access to [the] antigenic target site in . . . viable cell[s]” and will only bind cells that are already dead (id., page 9).

The present invention is directed to methods of treating cancer using “biological agents,” in this case, polyclonal or monoclonal antibodies which bind the extracellular domain of PSMA. Appellant describes four “particularly preferred” biological agents, monoclonal antibodies E99, J415, J533 and J591, to be “used alone or as a component in a mixture with other antibodies or other biological agents” (id., page 24). “In a particularly preferred embodiment . . . a first biological agent is conjugated with a

prodrug . . . [and] [t]he prodrug activator is conjugated with a second biological agent . . . preferably one which binds to a non-competing site” on PSMA. “Whether two biological agents bind to competing or non-competing binding sites can be determined by conventional competitive binding assays” (id., pages 32-33). For example, “[a] competition study was carried out to determine whether J591, J533, E99, and J415 detected the same or different antigenic sites (epitopes) of [PSMA]” (id., page 42). “The results indicated that J591, J533, and E99 each interfere, compete, or block binding of one another but do not block binding of J415 and vice versa” (id., page 43).

DISCUSSION

According to the examiner, “the specification [] provides a written description and indicates possession of a genus of antibodies that bind to the extracellular domain of PSMA and four species of such monoclonal antibodies, or species of the genus, e.g. E99, J591, J415, or J533[,]” but does not provide descriptive support for “a subgenus of antibodies that ‘compete for binding’ to E99, J591, J415, or J533” (Answer, pages 3-4). Consequently, the examiner has allowed claims 58-69, which require antibodies that bind the extracellular domain of PSMA, or which require monoclonal antibodies E99, J591, J415, or J533 in particular, but has rejected claims 72, 73, 84-111 and 113, which require antibodies that compete with E99, J591, J415, or J533, under 35 U.S.C. § 112, first paragraph.

Claims 58, 67 and 68 are representative of subject matter allowed by the examiner:

58. A method for treating non-prostate cancer in a subject comprising:
providing an antibody or antigen binding portion thereof which binds to the extracellular domain of prostate specific membrane antigen; and
administering the antibody or antigen binding portion thereof to a subject in need of treatment under conditions effective to treat non-prostate cancer.

67. The method according to claim 58, wherein the antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

68. The method according to claim 67, wherein the antibody is a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

Claim 72 is representative of the subject matter that is the subject of this appeal:

72. The method according to claim 58, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen (PSMA) with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

Essentially, the examiner's position is that "antibodies that 'compete for binding' to E99, J591, J415, and J533 . . . constitute a separate subgenus" that was not expressly "recite[d] or reasonably contemplate[d]" in the specification as originally filed (Answer, page 4). Further, the examiner asserts that the only relevant example in the specification "reinforce[s] the idea that 'non-competing' antibodies are [] preferred" (*id.*, page 8).

"The 'written description' requirement serves a teaching function, . . . in which the public is given 'meaningful disclosure in exchange for being excluded from practicing the invention for a limited period of time.'" University of Rochester v. G.D. Searle & Co., Inc., 358 F.3d 916, 922, 69 USPQ2d 1886, 1891 (Fed. Cir. 2004) (citation omitted). Another "purpose of the 'written description' requirement is . . . [to] convey with reasonable clarity to those skilled in the art that, as of the filing date [], [the applicant] was in possession of the invention." Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). See also Enzo Biochem Inc. v. Gen-Probe Inc., 296 F.3d 1316, 1329, 63 USPQ2d 1609, 1617 (Fed. Cir. 2002). The requirement is satisfied when the specification "set[s] forth enough detail to allow a person of ordinary skill in the art to understand what is claimed and to recognize that

the inventor invented what is claimed.” University of Rochester, 358 F.3d at 928, 69 USPQ2d at 1896. Whether or not a specification satisfies the requirement is a question of fact, which must be resolved on a case-by-case basis (Vas-Cath, 935 F.2d at 1562-63, 19 USPQ2d at 1116).

Much has been said on both sides of this issue, but we agree with appellant that the specification describes the disputed subgenus of antibodies, and that this “is not a close case” (Reply Brief, page 1). The specification describes a “process [which] involves providing a biological agent which . . . recognizes the extracellular domain of prostate specific membrane antigen” (Specification, page 9). “Preferred biological agents for use in the method . . . are antibodies or binding portions thereof, probes or ligands” (id., page 10). The specification further describes four “particularly preferred” monoclonal antibodies which bind the extracellular domain of PSMA (id., page 24). Three of the antibodies, J591, J533, and E99, “interfere, compete, or block binding of one another” to the same epitope on PSMA, but “do not block binding of [the fourth antibody,] J415[,] and vice versa” (id., page 43). Moreover, the specification teaches that “[s]uitable probes or ligands are molecules which bind to the . . . antigens identified by the monoclonal antibodies of the present invention” (id., page 24), i.e., molecules which bind the epitopes identified by J591, J533, E99 and J415.

Thus, the specification explicitly describes both competing and non-competing antibodies, and also teaches that other biological agents that bind, or recognize, the same sites identified by J591, J533, E99 and J415 are suitable for use in the claimed method. While it is true that the specification does not explicitly state that other antibodies are included among suitable “molecules which bind to the . . . antigens identified by the monoclonal antibodies of the present invention,” we conclude that

appellant's disclosure as a whole reasonably conveys to one of skill in the art that appellant was in possession of a "method . . . wherein the antibody . . . competes for binding to prostate specific membrane antigen [] with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533 and a J591 monoclonal antibody" (claim 72), as of the filing date of this application.

The rejection of claims 72, 73, 84-111 and 113 under the first paragraph of 35 U.S.C. § 112 is reversed.

REVERSED



Toni R. Scheiner
Administrative Patent Judge



Demetra J. Mills
Administrative Patent Judge



Eric Grimes
Administrative Patent Judge

)
)
)
)
)
) BOARD OF PATENT
)
) APPEALS AND
)
) INTERFERENCES
)
)
)
)

Appeal No. 2006-0352
Application No. 09/929,546

Page 7

Fish & Richardson PC
P.O. Box 1022
Minneapolis MN 55440-1022